Mineralys Therapeutics, Inc.
MLYS
$14.25
$0.755.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -100.69% | -147.55% | -237.81% | -149.90% | -168.81% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 395.07% | 211.20% | 103.54% | -200.00% | -217.19% |
| Change in Net Operating Assets | -394.83% | 39.02% | 243.71% | 20,885.25% | -332.46% |
| Cash from Operations | -130.64% | -163.71% | -47.88% | -49.82% | -184.52% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,133.13% | 1,887.57% | 147.93% | 60.15% | -116.18% |
| Cash from Investing | 1,133.13% | 1,886.65% | 147.93% | 60.11% | -116.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 85.14% | -78.26% | -- | -42.89% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 21.62% | -100.54% | 73.84% | -42.92% | 106.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 145.46% | 298.23% | 39.20% | -18.66% | -195.48% |
